Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tri Prime Gene Pharmaceutical Co FCF Margin % Chart
Beijing Tri Prime Gene Pharmaceutical Co Annual Data
BJSE:920344 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Beijing Tri Prime Gene Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tri Prime Gene Pharmaceutical Co FCF Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) has a FCF Margin % of 21.31% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Beijing Tri Prime Gene Pharmaceutical Co and its competitors. This is 766% above median its historical median of 2.46. According to the industry distribution chart, Beijing Tri Prime Gene Pharmaceutical Co ranks #108 out of 952 companies in the Biotechnology industry, placing it in the top 11.3%.
Is Beijing Tri Prime Gene Pharmaceutical Co's FCF Margin % too high?
Beijing Tri Prime Gene Pharmaceutical Co's current FCF Margin % of 21.31% is 766% above median its 10-year median of 2.46. Based on the distribution chart, Beijing Tri Prime Gene Pharmaceutical Co ranks #108 out of 952 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Tri Prime Gene Pharmaceutical Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tri Prime Gene Pharmaceutical Co's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Tri Prime Gene Pharmaceutical Co ranks #108 out of 952 companies for FCF Margin %. This places Beijing Tri Prime Gene Pharmaceutical Co in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Beijing Tri Prime Gene Pharmaceutical Co and its competitors. Beijing Tri Prime Gene Pharmaceutical Co's current FCF Margin % is 21.31%, which is 766% above median its own 10-year median of 2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tri Prime Gene Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥25.94, compared to a current price of ¥18.55 — trading 28.5% below its estimated fair value. The current FCF Margin % is 21.31%, which is 766% above median its 10-year median of 2.46. Beijing Tri Prime Gene Pharmaceutical Co's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344), the current FCF Margin % is 21.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tri Prime Gene Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥18.55 is trading 28.5% below its estimated GF Value™ of ¥25.94.
GuruFocus considers Beijing Tri Prime Gene Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for BJSE:920344:
FCF Margin %: 21.31% (766% above median its 10-year median of 2.46)
GF Value™: ¥25.94 vs. price of ¥18.55 (28.5% below fair value)
No single metric tells the full story. See the BJSE:920344 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tri Prime Gene Pharmaceutical Co Ltd is mainly engaged in the research, development, production, and sales of medical biotechnology products, including genetic engineering drugs, genetic engineering vaccines, and diagnostic reagents, and is engaged in related technical trade and technical consulting services. Its product line comprises Yundex Spray, Yundex Eye Drops, Yundexol Powder Injection, and Yundexol Water Injection.
77GF Score
Get the complete analysis for BJSE:920344
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920344 has been successfully added to your 
